New anticoagulants add to the therapeutic options for patients with atrial fibrillation, and offer
a number of advantages over warfarin, for both the clinician and patient, including a …

Atrial fibrillation is the commonest arrhythmia worldwide and is a growing problem. AF is
responsible for 25% of all strokes, and these patients suffer greater mortality and disability …

Traditionally, warfarin has been used to prevent stroke in patients with atrial fibrillation (AF),
but data from large, multinational, prospective, randomized studies suggest that novel oral …

Atrial fibrillation (AF) is an important cause of stroke, and stroke risk stratification is critical to
the management of patients with AF. Anticoagulation with warfarin is the current standard of …

Atrial fibrillation (AF) is a major and widely recognized risk factor for cardioembolic stroke.
Prophylactic therapy for the prevention of stroke in patients with AF is often achieved through …

Atrial fibrillation is responsible for more disability than any other cardiac arrhythmia because
of its high incidence and the considerable potential for adverse outcomes. There is …

ContextWarfarin has been shown to be highly efficacious for preventing thromboembolism in
atrial fibrillation in randomized trials, but its effectiveness and safety in clinical practice is …

Nonvalvular atrial fibrillation (AF) is an independent risk factor for stroke that becomes
increasingly prevalent as populations age. More than half a dozen clinical trials have …

Atrial fibrillation (AF) occurs in epidemic proportion and is now recognised to occur in about
2% of the general population. Its prevalence is age-related–about 10% of 80-year-olds have …

Clinical trials during the past 20 years have revolutionized the antithrombotic management
of atrial fibrillation. Based on consideration of 30 randomized trials involving 29,017 …